IBM Watson Health has inked a licensing agreement with Tel Aviv-based startup MedyMatch to integrate its MedyMatch’s A.I.-based clinical decision support app to help doctors identify instances of intracranial bleeding as a result of head trauma and stroke.
As part of the integration, IBM Watson’s Health Group will distribute the MedyMatch brain bleed detection application globally through its vendor neutral sales channels. Both companies have future plans to develop further interoperability between MedyMatch’s app and IBM Watson Health Imaging’s offerings.
Founded in 2013, MedyMatch utilizes advanced cognitive analytics and artificial intelligence to bring cognitive tools into the daily workflow of an emergency department to help physicians assess patients suspected of head trauma or stroke, and rule out the presence of a bleed in the brain. Physicians using the A.I.-based platform can automatically identify regions of interest that could indicate the potential presence of cerebral bleeds –and does so without interrupting how a physician works. The end result is acute emergency room treatment rather than life-long management of chronic conditions.
“The opportunity to license our deep vision application to IBM Watson Health creates a unique value proposition in healthcare,” said Gene Saragnese, chairman & chief executive officer of MedyMatch in a statement. “Engaging closely with IBM allows for a near-zero footprint implementation at a customer location delivering ‘A.I. to the bedside’ where I believe the future of healthcare lies. At MedyMatch, we believe improvements in the interpretation of data will lead to better decisions, better decisions will lead to better outcomes for patients and lower cost for healthcare. This is what drives us forward every day. “
MedyMatch is currently conducting a clinical trial for its intracranial bleed assessment application and is working towards a PMA Class III approval by the U.S. FDA.
